Core Viewpoint - Mirxes-B (02629) has seen a significant stock price increase, rising over 150% from its IPO price of 23.3 HKD, reaching a high of 59.5 HKD, and currently trading at 54.75 HKD with a trading volume of 566 million HKD [1] Company Overview - Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company has one core product, GASTROClearTM, along with two other commercialized products, LUNGClearTM and FortitudeTM, and six candidates in preclinical stages [1] Product Details - GASTROClearTM is a blood-based miRNA detection kit consisting of 12 miRNA biomarkers for gastric cancer screening, which received Class C in vitro diagnostic (IVD) certification from the Health Sciences Authority (HSA) of Singapore in May 2019 and has been successfully commercialized in Singapore [1] Market Inclusion - Mirxes has been included in the Hang Seng Composite Index, effective from September 8, which has contributed to its stock price surge and its designation as a stock eligible for the Shanghai-Hong Kong Stock Connect [1]

中化新网讯 近日，中国科学院天津工业生物技术研究所在亚胺还原酶催化动态动力学拆分还原胺化合 成双手性中心N-取代氨基酰胺和氨基酯研究中取得新进展，为这类重要手性化合物的绿色高效合成提 供了新方法。 研究人员通过对亚胺还原酶酶库的筛选及蛋白质工程改造，获得了催化性能显著提升的突变体，该突变 体的催化效率较野生型酶提高了102倍。利用该工程酶，团队成功实现了抗癫痫药物布瓦西坦的克级规 模制备，并合成了一系列具有双手性中心的N-取代氨基酰胺、氨基酯及其内酰胺。通过晶体结构分析 与分子动力学模拟，研究人员揭示突变酶活性提高的机制。该研究为双手性中心氨基酸衍生物及其内酰 胺的高效、绿色不对称合成提供了新的生物催化策略，拓展了生物催化剂在动态动力学拆分还原胺化反 应中的应用范围。 据介绍，手性N-取代氨基酰胺和氨基酯是多种药物和农药的关键结构单元。该类化合物尤其是含多个 手性中心的N-取代氨基酰胺/氨基酯的高效不对称合成一直存在挑战。传统化学合成方法往往依赖苛刻 反应条件或贵金属催化剂，且难以精确控制还原胺化过程中的立体选择性。因此，开发生物合成方法具 有重要意义。 ...

Core Insights - A 67-year-old American man, Tim Andrews, has survived six months after receiving a genetically modified pig kidney transplant, marking a significant milestone in organ transplantation [1] - The transplant was performed under the "compassionate use" principle, allowing the use of unapproved treatments for patients in critical need [1] - The pig kidney was sourced from a genetically edited pig, which underwent three modifications to reduce rejection risks and complications [1] Group 1 - The six-month survival period post-transplant is considered the most critical phase for patients, with potential complications including anemia and immune rejection [1] - Successful survival beyond six months is viewed optimistically, with a further milestone anticipated at twelve months [1] - The previous record for the longest survival of a genetically modified pig organ was four months and nine days, achieved by a 53-year-old woman, Tawana Rooney, before experiencing rejection [1]

Core Viewpoint - The article discusses the recent inclusion of three Chinese biotechnology companies in the U.S. Entity List, highlighting the ongoing tensions in the biotechnology sector between the U.S. and China, particularly in relation to national security concerns and technological competition [2][3]. Group 1: U.S. Policy Developments - On September 12, the U.S. Department of Commerce's Bureau of Industry and Security (BIS) announced the addition of 23 Chinese entities to the Entity List due to actions deemed contrary to U.S. national security or foreign policy interests, including three from the biotechnology and life sciences sector [2]. - The entities listed will require export licenses for all items governed by the Export Administration Regulations (EAR), with a presumption of denial for such licenses, indicating a significant barrier for these companies in international trade [2]. Group 2: Companies Listed - The three biotechnology companies added to the Entity List are: 1. Beijing Tianyi Huiyuan Biotech, established in 2008, focuses on gene sequence detection, gene synthesis, gene editing, and protein expression vector assembly, serving various hospitals and research institutions [3]. 2. Beijing Tsingke Biotech Co., Ltd., founded in 2017, operates as a comprehensive gene synthesis platform, providing a range of services including gene synthesis, antibody proteins, and molecular reagents, and has attracted significant investment, including a B-round financing of 400 million RMB [4]. 3. Sangon Biotech (Shanghai) Co., Ltd., founded in 2003, offers over 20,000 products across seven categories, including DNA synthesis and sequencing, and has a global presence in 147 countries, recognized as a major player in the DNA synthesis market [5].

Group 1 - Recent foreign capital inflow into the Chinese market has reached its highest monthly net purchase since September 2024, with a significant shift towards onshore markets [1][3] - The increase in foreign investment is attributed to China's leading position in advanced fields such as artificial intelligence and robotics, as well as positive signals from recent economic stabilization policies [1][4] - High-growth technology, high-dividend assets, and high-end manufacturing are the primary sectors attracting foreign investment [1][6] Group 2 - Foreign investors' interest in the Chinese market is on the rise, with over 90% of surveyed U.S. investors indicating plans to increase their exposure, the highest level since early 2021 [4] - The trading activity of foreign capital has significantly increased, with a notable rise in participation through ETFs and programmatic trading rules [4][5] - The structure of foreign investment is shifting from defensive to offensive, with a focus on technology growth and high-end manufacturing, driven by policy and valuation factors [7][8] Group 3 - The average daily trading volume of northbound funds in ETFs reached 3.282 billion yuan in July, indicating a substantial increase in foreign participation [5] - The overall net inflow of overseas funds into the A-share market reached 836 billion yuan by the end of June, with a significant concentration in the information technology and industrial sectors [7] - The recent rise in the A-share market is driven by multiple factors, including policy adjustments, improved liquidity, and enhanced economic fundamentals [8]

Core Viewpoint - The U.S. Department of Commerce has added 23 Chinese entities to its Entity List, bringing the total to 1,112 Chinese companies on the list, citing national security and foreign policy concerns [1][2]. Group 1: Entities Listed - The 23 entities include 13 related to semiconductors and integrated circuits [3]. - Three entities are involved in biotechnology and life sciences [4]. - Two entities are research institutes related to aerospace, quantum technology, and timing systems [5]. - Two entities are related to industrial and engineering software [5]. - Three entities are involved in supply chain and logistics services [7]. Group 2: Reasons for Listing - The U.S. government claims these entities are involved in acquiring U.S. origin items for China's modernization, aerospace defense, and quantum technology development [2]. - They are also accused of supporting advanced computing, integrated circuit manufacturing, and distribution, directly serving government and security systems [2]. - There are concerns regarding their participation in biotechnology, engineering software development, and semiconductor manufacturing equipment procurement, with risks of circumventing export controls [2]. Group 3: Export Control Implications - All items controlled under the Export Administration Regulations (EAR), including hardware, software, and technology, require a license from the U.S. Department of Commerce for export, re-export, or domestic transfer to the listed entities [7].

Core Points - The company is changing its official website and investor email domain to enhance its brand image [1] - The new website and email will be effective from September 15, 2025, with a transition period until March 15, 2026 [1] - During the transition, the old website will automatically redirect to the new one, and emails sent to the old investor email will be forwarded to the new one [1] - The company's investor contact number, fax, and address will remain unchanged [1]

Company Summaries - Robin Energy Ltd. (NASDAQ:RBNE) experienced a significant stock price decrease of approximately 39.56%, now trading at $1.39, potentially due to its announcement of a public offering of 5.77 million shares at $1.30 per share, aiming to raise about $7.5 million, expected to close around September 12, 2025 [1][7] - Lexaria Bioscience Corp. (LEXXW) saw a 33.05% drop in its stock price to $0.06, influenced by the volatile nature of the biotech sector, possibly due to regulatory news or clinical trial results [2][7] - Ethzilla Corp. (ETHZW) experienced a 32.6% decline in stock price to $0.06, highlighting the impact of the volatile cryptocurrency market on digital asset management companies [3][7] - NeuroSense Therapeutics Ltd. (NRSNW) witnessed a 30.18% decline in its stock price to $0.37, with sensitivity to news related to its lead product candidate, PrimeC, and other pipeline developments [4] - Sentage Holdings Inc. (NASDAQ:SNTG) saw its stock price fall by 28.04% to $2.9, potentially impacted by regulatory changes in China's financial sector and broader economic factors affecting the Chinese market [5] Industry Insights - The movements in stock prices underscore the diverse range of factors influencing them, from industry-specific developments to broader economic trends [6] - The biotech sector is characterized by volatility, with companies' valuations heavily dependent on their pipelines' progress and potential market opportunities [2] - The cryptocurrency market's volatility significantly affects companies like Ethzilla, which focus on digital asset management and yield generation strategies [3]

Core Insights - The launch of the Biotech Fund by Sarat Ventures Y Innovations Biotech Fund (UK) aims to establish Saudi Arabia as a global biotechnology hub, with an investment of approximately $50 million targeting biotech companies strategically linked to the Saudi market and the broader MENA region [1][2][3] - The initiative is part of Saudi Arabia's "Vision 2030" strategy to diversify its economy through knowledge-based industries, marking a significant step in accelerating innovation in the life sciences sector [1][2] Group 1 - The fund is led by Dr. Megan Yung and Dr. Huda Alfardus, who bring extensive experience and regional expertise to the initiative, facilitating seamless entry and sustained growth for portfolio companies in Saudi Arabia [2][3] - Y Innovations Group is recognized for its rigorous due diligence, strong investment capabilities, and successful track record in transforming early scientific concepts into world-class therapies [2] Group 2 - The Saudi biotechnology industry is projected to reach a size of $11 billion to $12 billion by 2030, and the fund aims to leverage strategic partnerships within the market [3] - The fund is positioned to set a new benchmark for biotech venture capital in the Middle East and beyond, utilizing deep due diligence expertise and unparalleled access to Saudi Arabia's strategic infrastructure [3]

Core Viewpoint - American investors' interest in Chinese stocks is at a five-year high, with their return to the Chinese market just beginning [1][4]. Group 1: Investor Sentiment - Over 90% of investors expressed a willingness to increase exposure to the Chinese market, marking the highest level since early 2021 [3]. - The interest from American investors extends beyond U.S.-listed Chinese stocks to onshore A-shares, with quantitative and macro funds increasing investments through ETFs and index futures [5]. Group 2: Market Conditions - Chinese policymakers are gradually taking steps to stabilize the economy and boost the stock market, suggesting that the worst period may be over [5]. - The Shanghai Composite Index has rebounded over 40% since last September, with a nearly 19% increase this year, raising hopes for a slow bull market [5]. Group 3: Recent Data - In August, foreign investors injected nearly $45 billion into emerging market stocks and bonds, with $39 billion flowing into Chinese bonds and stocks [6]. - Global hedge funds recorded the highest net purchases of Chinese assets since September of last year, with total positions reaching a two-year high [7].